Three targets of branched-chain amino acid supplementation in the treatment of liver disease.
The article explains the pathogenesis of disturbances in branched-chain amino acid (BCAA; valine, leucine, and isoleucine) and protein metabolism in various forms of hepatic injury and it is suggested that the main cause of decrease in plasma BCAA concentration in liver cirrhosis is hyperammonemia. Three possible targets of BCAA supplementation in hepatic disease are suggested: (1) hepatic encephalopathy, (2) liver regeneration, and (3) hepatic cachexia. The BCAA may ameliorate hepatic encephalopathy by promoting ammonia detoxification, correction of the plasma amino acid imbalance, and by reduced brain influx of aromatic amino acids. The influence of BCAA supplementation on hepatic encephalopathy could be more effective in chronic hepatic injury with hyperammonemia and low concentrations of BCAA in blood than in acute hepatic illness, where hyperaminoacidemia frequently develops. The favorable effect of BCAA on liver regeneration and nutritional state of the body is related to their stimulatory effect on protein synthesis, secretion of hepatocyte growth factor, glutamine production and inhibitory effect on proteolysis. Presumably the beneficial effect of BCAA on hepatic cachexia is significant in compensated liver disease with decreased plasma BCAA concentrations, whereas it is less pronounced in hepatic diseases with inflammatory complications and enhanced protein turnover. It is concluded that specific benefits associated with BCAA supplementation depend significantly on the type of liver disease and on the presence of inflammatory reaction. An important task for clinical research is to identify groups of patients for whom BCAA treatment can significantly improve the health-related quality of life and the prognosis of hepatic disease.
Holecek
Milan
M
Department of Physiology, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Czech Republic. holecek@lfhk.cuni.cz
D000597:Amino Acids, Branched-Chain / Q000008:administration & dosage* / Q000097:blood / Q000172:deficiency; D002100:Cachexia / Q000188:drug therapy / Q000209:etiology; D019587:Dietary Supplements; D006501:Hepatic Encephalopathy / Q000188:drug therapy; D006801:Humans; D022124:Hyperammonemia / Q000097:blood / Q000188:drug therapy; D008107:Liver Diseases / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008115:Liver Regeneration
D000597:Amino Acids, Branched-Chain